ID

43789

Description

An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications; ODM derived from: https://clinicaltrials.gov/show/NCT02082249

Link

https://clinicaltrials.gov/show/NCT02082249

Keywords

  1. 5/1/16 5/1/16 -
  2. 9/20/21 9/20/21 -
Uploaded on

September 20, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Advanced Parkinson's Disease NCT02082249

Eligibility Advanced Parkinson's Disease NCT02082249

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects completing 12 weeks treatment in study m12-921 who would benefit from long-term treatment from abt-slv187. alternatively, subjects who (i) participated in the phase 2 study m12-925 (ii) would, in the opinion of the investigator, benefit from abt-slv187 treatment in the study m12-923, (iii) did not discontinue the m12-925 study due to safety reason, and (iv) meet all entry requirements.
Description

Carbidopa / Levodopa

Data type

boolean

Alias
UMLS CUI [1]
C0353697
the subject must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study procedures (including any changes occurring in the subject's current therapeutic regimen).
Description

informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
the subject must be willing to continue on treatment.
Description

Previous treatment continue

Data type

boolean

Alias
UMLS CUI [1]
C0420262
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
subject is enrolled in another clinical trial
Description

subject is enrolled in another clinical trial

Data type

boolean

Alias
UMLS CUI [1]
C2348568
psychiatric, neurological or behavioral disorders that may interfere with the ability of subjects to give informed consent, or interfere with the conduct of the study.
Description

interfere with patient

Data type

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2]
C0525058
UMLS CUI [3]
C0004936
medical, laboratory, or surgical issues deemed by the investigator to be clinically significant and in the opinion of the pi, would be a contraindication to continued levodopa therapy.
Description

contraindication to continued levodopa therapy

Data type

boolean

Alias
UMLS CUI [1]
C1301624
UMLS CUI [2]
C0023570
uncooperative attitude or reasonable likelihood for non-compliance with the protocol
Description

Patient Non-Compliance

Data type

boolean

Alias
UMLS CUI [1]
C0376405
subject has current significant suicidal ideation as evidenced by answering "yes" to questions 4 or 5 on the suicidal ideation portion of the columbia-suicide severity rating scale completed at the week 12 visit of study m12-921 or at the baseline visit of the current study for m12-925 study subjects.
Description

suicidal ideation

Data type

boolean

Alias
UMLS CUI [1]
C0424000
consideration by the investigator, for any reason, that the subject is an unsuitable candidate to continue to receive abt-slv187
Description

unsuitable candidate to continue to receive

Data type

boolean

Alias
UMLS CUI [1,1]
C3839545
UMLS CUI [1,2]
C2002915

Similar models

Eligibility Advanced Parkinson's Disease NCT02082249

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Carbidopa / Levodopa
Item
subjects completing 12 weeks treatment in study m12-921 who would benefit from long-term treatment from abt-slv187. alternatively, subjects who (i) participated in the phase 2 study m12-925 (ii) would, in the opinion of the investigator, benefit from abt-slv187 treatment in the study m12-923, (iii) did not discontinue the m12-925 study due to safety reason, and (iv) meet all entry requirements.
boolean
C0353697 (UMLS CUI [1])
informed consent
Item
the subject must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study procedures (including any changes occurring in the subject's current therapeutic regimen).
boolean
C0021430 (UMLS CUI [1])
Previous treatment continue
Item
the subject must be willing to continue on treatment.
boolean
C0420262 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
subject is enrolled in another clinical trial
Item
subject is enrolled in another clinical trial
boolean
C2348568 (UMLS CUI [1])
interfere with patient
Item
psychiatric, neurological or behavioral disorders that may interfere with the ability of subjects to give informed consent, or interfere with the conduct of the study.
boolean
C0525058 (UMLS CUI [1])
C0525058 (UMLS CUI [2])
C0004936 (UMLS CUI [3])
contraindication to continued levodopa therapy
Item
medical, laboratory, or surgical issues deemed by the investigator to be clinically significant and in the opinion of the pi, would be a contraindication to continued levodopa therapy.
boolean
C1301624 (UMLS CUI [1])
C0023570 (UMLS CUI [2])
Patient Non-Compliance
Item
uncooperative attitude or reasonable likelihood for non-compliance with the protocol
boolean
C0376405 (UMLS CUI [1])
suicidal ideation
Item
subject has current significant suicidal ideation as evidenced by answering "yes" to questions 4 or 5 on the suicidal ideation portion of the columbia-suicide severity rating scale completed at the week 12 visit of study m12-921 or at the baseline visit of the current study for m12-925 study subjects.
boolean
C0424000 (UMLS CUI [1])
unsuitable candidate to continue to receive
Item
consideration by the investigator, for any reason, that the subject is an unsuitable candidate to continue to receive abt-slv187
boolean
C3839545 (UMLS CUI [1,1])
C2002915 (UMLS CUI [1,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial